{"id":"W4308963956","doi":"10.1097/hs9.0000000000000801","title":"Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":true,"ca_institutions":"Saint John Regional Hospital; University of New Brunswick","funders":"Janssen Biotech; Novo Nordisk; Ascentage Pharma; Servier; Moderna; Celltrion; Incyte; Pharmacyclics; MEI Pharma; Karyopharm Therapeutics; Gilead Sciences; BeiGene; Sanofi; Cilag; TG Therapeutics; Pfizer; MorphoSys; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Internal medicine; Bendamustine; Chronic lymphocytic leukemia; Tolerability; Ofatumumab; Gastroenterology; Adverse effect; Oncology; Leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001304056,0.0004750407,0.0008210692,0.0002462314,0.000341912,0.00004568945,0.0005999194,0.000355101,0.003473011],"category_scores_gemma":[0.004126677,0.0004869902,0.0002724574,0.00130898,0.000347533,0.0001473285,0.000677428,0.002007885,0.0004633766],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.265405,"about_ca_system_score_gemma":0.1279601,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004689221,"about_ca_topic_score_gemma":0.0008877887,"domain_scores_codex":[0.9941876,0.0004577825,0.001101328,0.001135978,0.001818767,0.001298531],"domain_scores_gemma":[0.9961385,0.001344746,0.0002868712,0.001346135,0.0001044352,0.0007792762],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6186721,0.001320362,0.0004312495,0.001683952,0.0006555413,0.009717964,0.002310622,0.015763,0.003527805,0.001044155,0.3273049,0.01756841],"study_design_scores_gemma":[0.7278039,0.005290357,0.0003312984,0.0002407996,0.0001244293,0.00028828,0.0004834612,0.02065491,0.0009699707,0.00005847884,0.2432011,0.0005530145],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.971468,0.003054276,0.000002061138,0.0006219083,0.001655117,0.001740929,0.00005344927,0.0002327786,0.02117149],"genre_scores_gemma":[0.9826602,0.0001178496,0.0002033387,0.0005881799,0.001512242,0.0005201862,0.000189965,0.0001327582,0.01407531],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1374449,"threshold_uncertainty_score":0.9997582,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07152014511977556,"score_gpt":0.3352977625918449,"score_spread":0.2637776174720693,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}